NCT01509911

A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: Tiltan Pharma Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase II clinical trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated Pancreatic Cancer patients

Conditions

• Metastatic Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	TL-118	TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
DRUG	Gemcitabine	Monthly cycles of 3 weekly treatments a month and one week off of treatment

Timeline

• Start date: 2012-01-01
• Primary completion: 2016-10-01
• Completion: 2017-01-01
• First posted: 2012-01-13
• Last updated: 2016-02-05

Locations

10 sites across 2 countries: United States, Israel